This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Lower Patient Days Hurt Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect growth in adjusted admissions and operating expenses.
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 58.2% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Alector (ALEC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 130.77% and 64.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -245.95% and 73.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 2nd
by Zacks Equity Research
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -423.08% and 81.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alector (ALEC) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector's (ALEC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
by Zacks Equity Research
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
by Zacks Equity Research
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.